The history of Viagra presents a challenging picture for investors. While the initial release generated substantial returns, the end of its intellectual property protection opened the floodgates to off-brand alternatives, dramatically diminishing revenue. This poses a particular dilemma for drug manufacturers relying on comparable blockbuster offer

The legacy of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, generating billions in sales , its patent expiration created a flood of knock-off medications, significantly diminishing its dominance. While certain firms may try to capitalize on similar conditions , the present